RedHill Biopharma (RDHL) Posts Q3 Loss of 7c/Share

RedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of ($0.07), $0.51 better than the analyst estimate of ($0.58).

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Nvidia underperforms peers as report sparks rack delay worries
• HSBC sees more upside in Intel stock on server CPU opportunity
• Retail investors largely unaware of SEC semiannual reporting proposal